White & Case LLP, a global law firm, recently advised Merck KGaA, Darmstadt, Germany (MKDG), a leading science and technology company, on their agreement to acquire Mirus Bio, a life science company, for US$600 million. Mirus Bio specializes in the development and commercialization of transfection reagents, which are essential in the production of viral vectors for cell and gene therapies. This acquisition will enhance MKDG’s offerings in viral vector manufacturing and complement their existing portfolio for the development and production of novel modalities such as cell and gene therapies, which are key growth areas for their life science business sector.
The transaction with Gamma Biosciences, a life sciences platform established by global investment firm KKR for the acquisition of Mirus Bio, is expected to close in the third quarter of 2024. However, the completion of the deal is subject to regulatory clearance and other customary closing conditions.
The White & Case team that worked on this transaction was led by partners Stefan Koch (Frankfurt) and Caitlin Powell Gimpel (New York) and included several other partners and local partners from various locations. The team also included counsel and associates from different offices, showcasing the firm’s global reach and expertise in complex cross-border transactions.
For more information about this transaction, please contact your local media representative.